🇺🇸 FDA
Pipeline program

Attentin 10 mg Tablette, Dexamfetamine sulfate 20 mg modified-release capsule, Placebo for Test 1 - 5 mg, Attentin 5 mg, Tablette, Placebo for test 2 - 10 mg, Placebo for test 1 - 10 mg, Placebo for test 2 - 20 mg, Dexamfetamine sulfate 15 mg modified-release capsule, Placebo for test 2 - 15 mg, Dexamfetamine sulfate 10 mg modified-release capsule

6520-9970-08

Phase 3 small_molecule active

Quick answer

Attentin 10 mg Tablette, Dexamfetamine sulfate 20 mg modified-release capsule, Placebo for Test 1 - 5 mg, Attentin 5 mg, Tablette, Placebo for test 2 - 10 mg, Placebo for test 1 - 10 mg, Placebo for test 2 - 20 mg, Dexamfetamine sulfate 15 mg modified-release capsule, Placebo for test 2 - 15 mg, Dexamfetamine sulfate 10 mg modified-release capsule for Patients with ADHD (according to ICD-10 / DSM-5) is a Phase 3 program (small_molecule) at Medice Arzneimittel Pütter GmbH & Co. KG with 1 ClinicalTrials.gov record(s).

Program details

Company
Medice Arzneimittel Pütter GmbH & Co. KG
Indication
Patients with ADHD (according to ICD-10 / DSM-5)
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials